Helius Medical Technologies, Inc. (HSDT)
NASDAQ: HSDT · Real-Time Price · USD
1.090
-0.050 (-4.39%)
At close: Jun 6, 2025, 4:00 PM
1.090
0.00 (0.00%)
After-hours: Jun 6, 2025, 6:26 PM EDT
HSDT Employees
Helius Medical Technologies had 21 employees as of December 31, 2024. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
$20,667
Profits / Employee
-$622,095
Market Cap
575.59K
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
HSDT News
- 1 day ago - Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering - GlobeNewsWire
- 2 days ago - Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria - GlobeNewsWire
- 17 days ago - Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting - GlobeNewsWire
- 25 days ago - Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 5 weeks ago - Helius Medical Technologies Announces Reverse Stock Split - GlobeNewsWire
- 3 months ago - Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary - GlobeNewsWire
- 3 months ago - Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - GlobeNewsWire
- 4 months ago - Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study - GlobeNewsWire